Clinical trial · Interventional
Fludarabine/Busulfan and Cyclophosphamide Conditioning for Adult Lymphoid Malignancies
Fludarabine/Busulfan and Post-infusion Cyclophosphamide as Conditioning for Adult Patients With Lymphoid Malignancies Undergoing Allogeienc Stem Cell Transplantation
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Allogeneic stem cell transplantation is potential curative therapy for adult lymphoid malignancies. Based on our previous study, the condition with iv-busulfan (iv-BU) and cyclophosphamide (CTX) is feasible with low toxicity and transplantation mortality and long-term survival is comparable to most data reported with slightly higher relapse rate particularly for patients in CR2. In this study, the investigators aim to further improve the conditioning with Fludarabine + iv-BU and to use CTX after stem cell transfusion as consolidation for lymphoid malignancies and graft-versus-host disease (GVHD) prophylaxis.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoid Malignancies | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| FLu-Bu-Cy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- FLu-Bu-Cy
- description
- Patients received Fludarabine and iv Busulfan and post-infusion Cyclophosphamide as conditioning
- interventionNames
- Drug: FLu-Bu-Cy
Primary outcomes (2)
- measure
- acute graft versus host disease (GVHD)
- timeFrame
- day 100
- description
- d100 incidence of acute GVHD, grade II-IV or grade III-IV
- measure
- chronic GVHD
- timeFrame
- 3 years
- description
- 3-year incidence of chronic GVHD and extensive cGVHD
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * adult acute lymphocytic leukemia in 1st or second remission; lymphoid malignancies in 1st or second remission * age 16-60 years * with inform consent * no contraindication for allogeneic transplantation: active infection, allergy to FLu/Bu/CTX, liver and renal function damage * HLA matched related (6/6), unrelated donors (at least 8/10) or mismatched related donor (haplo) Exclusion Criteria: * age less than 16 years or over 60 years * liver function/renal function damage (over 2 X upper normal range) * with mental disease * other contraindication of all-HSCT
References
Publications (0)
Data not yet available